MedTrace Logo

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

NCT06553287 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-08-14

No results posted yet for this study

Summary

The purpose of the study is to evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment (0.3%, 1.0%, and 1.5%) vs vehicle twice daily (BID) in Adults Patients with Atopic Dermatitis.

Conditions

Interventions

DRUG

LNK01004 ointment 0.3%

LNK01004 ointment 0.3% for topical application

DRUG

LNK01004 ointment 1.0%

LNK01004 ointment 1.0% for topical application

DRUG

LNK01004 ointment 1.5%

LNK01004 ointment 1.5% for topical application

DRUG

Vehicle BID

Inactive vehicle matched to LNK01004 ointment for topical application.

Sponsors & Collaborators

  • Lynk Pharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Qianjin Lu · Hospital for skin diseases, Institute of Dermatology, Chinese Academy of Medical Sciences.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-12
Primary Completion
2024-06-18
Completion
2024-06-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06553287 on ClinicalTrials.gov